@K0byOBr1en
That confirms my calculations that there are some one off costs in the product manufacturing & operating costs. These will be associated with the WDA integration and/or something going on behind the scenes but is sensitive to release to the market at this stage.
Looking at the Q1 FY2021 4C you can calculate that product manufacturing & operating costs (PMOC) are about 75% of 4C revenue. Applying 75% cost base to $645,909 revenue equates to $484,432 PMOC. $850,544 Q2 FY2021 PMOC via 4C - $484,432 = $366,112 one off expenses.
R&D decreased by about $32k for the qtr = 23.6% down, Advertising & Marketing increased by about $75k = 256% up, Staff Costs increased by about $119k = 31.5% up, Admin & Corporate Costs increased by $21,000 = 4.7% up.
Appears that they bumped up Advertising & Marketing for the busy season & there are additional staff costs circa $476k pa being for all the new hires for the B2B launch.
- Forums
- ASX - By Stock
- KDY
- Ann: Quarterly Report
Ann: Quarterly Report, page-20
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KDY (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.834M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
KDY (ASX) Chart |
Day chart unavailable
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online